07 June 2018: Articles
Tenosynovitis with Rice Body Formation Due to Mycobacterium Intracellulare Infection After Initiation of Infliximab Therapy
Challenging differential diagnosis, Diagnostic / therapeutic accidents, Unusual setting of medical care, Rare disease, Educational Purpose (only if useful for a systematic review or synthesis)
Takeshi Saraya ABCDEF 1*, Kazuhito Fukuoka BCD 2, Hideto Maruno BCE 3, Yoshinori Komagata D 2, Masachika Fujiwara CD 4, Shinya Kaname CD 2, Yoshihiro Arimura CD 2, Akira Yamada CD 2, Hajime Takizawa D 5DOI: 10.12659/AJCR.908785
Am J Case Rep 2018; 19:656-662
Abstract
BACKGROUND: Rheumatoid arthritis tenosynovitis is difficult to discriminate from non-tuberculous tenosynovitis on the basis of radiological and pathological findings.
CASE REPORT: A 74-year-old woman with a 4-year history of rheumatoid arthritis was referred to our hospital to undergo treatment for uncontrollable tenderness and swelling in her right third metacarpophalangeal joint, right wrist, and left knee joint. In the previous year, she underwent surgery at a local hospital for the swelling in her right metacarpophalangeal joint, the information of which was not known precisely, but the swelling subsided in due course after an operation. We treated the patient with infliximab (monthly intravenous infusions of 150 mg), but 2 months later, she complained of exacerbation of the swelling in her right third metacarpophalangeal joint and right wrist, and fluid discharge that contained Mycobacterium intracellulare. After synovectomy and aggressive debridement in the palmar side of the right wrist, she was diagnosed as having granulomatous tenosynovitis caused by the M. intracellulare infection and abundant rice body formation in the right carpal tunnel area. We considered the rice bodies inside and outside the bursa, along with a history of tenosynovitis exacerbation after initiation of infliximab therapy (tumor necrosis factor alpha inhibitor [TNFi]), to be related to the M. intracellular infection.
CONCLUSIONS: Tenosynovitis caused by atypical mycobacteria is uncommon and usually affects the hand or wrist. Therefore, for early diagnosis, mycobacterial infection should be considered in cases of indolent chronic granulomatous tenosynovitis, especially in RA cases that recur after TNFi therapy is started.
Keywords: Arthritis, Rheumatoid, Granulomatous Disease, Chronic, Nontuberculous mycobacteria
Background
Tumor necrosis factor alpha inhibitors (TNFi) can increase the risk of both tuberculosis and non-tuberculous
Patients with early- and late-phase RA often exhibit rounded rice bodies that are mainly composed of fibrin, which correspond to a history of symptomatic joint involvement [3]. However, abundant rice body formation is rarely reported in cases of tuberculosis and non-tuberculous tenosynovitis, and the most common site is inside the bursa. We report a unique case of RA with abundant rice bodies inside and outside the bursa (in the carpal tunnel area and tendon sheaths) and tenosynovitis exacerbation after the initiation of TNFi therapy, which were likely caused by
Case Report
A 74-year-old woman presented with a 4-year history of RA (Steinbrocker classification: class I, 1987 American College of Rheumatology classification: stage I). She sought treatment because of uncontrollable tenderness and swelling in her right third metacarpophalangeal joint, right wrist on the palmar side, and left knee joint. For the last 4 years, she had been treated with salazosulfapyridine (1.0 g/day), prednisolone (10 mg/day), and methotrexate (MTX; 6 mg/week). A physical examination revealed swelling and erythema that extended from the right wrist to the palm. The right middle finger was also swollen and edematous and had a limited range of motion. Radiography of the hands and left knee joint revealed normal findings, with the exception of the soft tissue swelling (Figure 1A) and erosion of the radius (Figure 1B, arrow). Chest radiography revealed no pathological changes. Laboratory data revealed the following values (normal range): white blood cells, 9600/mL (4000–8000/mL); erythrocyte sedimentation rate, 35 mm/h (<25 mm/h); C-reactive protein, 1.7 mg/dL (<0.3 mg/dL); and matrix metalloproteinase 3, 335 ng/mL (17.3–59.7 ng/mL). The initial disease activity score 28 using C-reactive protein levels was 4.47, which suggested moderate activity. Therefore, we treated the patient with infliximab (150 mg once per month via intravenous infusion), in accordance with the existing guidelines for our region.
After 2 months of infliximab treatment, the tenderness and swelling in the right middle finger and right wrist significantly worsened (Figure 2). In addition, we observed a new induration in the right wrist, although the condition of the left knee improved. Furthermore, we observed fluid discharge from the right middle finger (Figure 2A, arrow) and right wrist (Figure 2B, arrow). Culture of the discharge revealed growth of
Discussion
We present a rare case of granulomatous tenosynovitis caused by
Rice bodies that were mainly composed of fibrin have been reported in cases of tuberculous infection, RA, and seronegative inflammatory arthritis [6]. However, abundant rice body formation is rare in both tuberculous tenosynovitis [6] and nontuberculous tenosynovitis [7,8]. RA tenosynovitis is difficult to discriminate from non-tuberculous tenosynovitis on the basis of radiological and pathological findings. Moreover, rice bodies in patients with RA are typically observed in the subacromial bursa and are rarely observed outside the bursa (e.g., in the tendon sheaths) [6]. In the present case, we observed abundant rice bodies inside and outside the bursa (i.e., in the tendon sheaths), which indicates that these findings were related to
The risk of infectious tenosynovitis is increased among patients with RA, mixed connective tissue disorders, diabetes mellitus, solid organ transplants, steroid medication, cancer, previous trauma, surgical procedure, and non-apparent inoculation (e.g., water contamination) [9,10]. To the best of our knowledge, only 4 reports/7 cases of infectious tenosynovitis after the initiation of TNFi have been described [11–14] (Table 1). In our review, we found that the time from onset to diagnosis ranged from several months to >3 years, and most cases required multiple surgeries. Surgical debridement is essential for treating infectious tenosynovitis, although the importance and optimal duration of antimycobacterial chemotherapy for mycobacterial tenosynovitis are unclear, as some infections are cured using surgery alone [15].
Curtis et al. [14] reported that the risk of infection is similar for TNFi and prednisone doses of >10 mg/day. In this context, our patient had been receiving MTX and prednisolone (10 mg/day), although her disease onset had not been precisely defined. Curtis et al. also found that TNFi treatment was associated with a 1.9-fold higher risk of infection than with MTX alone and that the incidence of infection increased by 4-fold within 6 months after initiation of TNFi therapy [16].
In summary, our case exhibited infectious granulomatous tenosynovitis caused by
Conclusions
A mycobacterial origin should be considered for patients who present with indolent chronic granulomatous tenosynovitis, especially in cases that recur after treatment with disease-modifying antirheumatic drugs and/or TNFis.
References:
1.. Winthrop KL, Yamashita S, Beekmann SE, Polgreen PM, Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: Case finding through the Emerging Infections Network: Clin Infect Dis, 2008; 46(11); 1738-40, pmid: 18419421
2.. Winthrop KL, Chang E, Yamashita S, Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy: Emerg Infect Dis, 2009; 15(10); 1556-61, pmid: 19861045
3.. Popert AJ, Scott DL, Wainwright AC, Frequency of occurrence, mode of development, and significance or rice bodies in rheumatoid joints: Ann Rheum Dis, 1982; 41(2); 109-17, pmid: 6176192
4.. Toussirot E, Chevrolet A, Wendling D: Clin Rheumatol, 1998; 17(2); 152-56, pmid: 9641515
5.. Anim-Appiah D, Bono B, Fleegler E: Arthritis Rheum, 2004; 51(1); 140-42, pmid: 14872467
6.. Hsu CY, Lu HC, Shih TT, Tuberculous infection of the wrist: MRI features: Am J Roentgenol, 2004; 183(3); 623-28, pmid: 15333346
7.. Chau CL, Griffith JF, Chan PT, Rice-body formation in atypical mycobacterial tenosynovitis and bursitis: Findings on sonography and MR imaging: Am J Roentgenol, 2003; 180(5); 1455-59, pmid: 12704068
8.. Nagasawa H, Okada K, Senma S, Tenosynovitis with rice body formation in a non-tuberculosis patient: A case report: Ups J Med Sci, 2009; 114(3); 184-88, pmid: 19736610
9.. Kozin SH, Bishop AT, Atypical Mycobacterium infections of the upper extremity: J Hand Surg Am, 1994; 19(3); 480-87, pmid: 8056979
10.. Sahinbegovic E, Arco G, Cavallaro A, A typically atypical tenosynovitis: Clin Rheumatol, 2013; 32(Suppl. 1); S87-88, pmid: 20582608
11.. Bauer AS, Blazar PE, Earp BE, Simmons BP, Mycobacterial hand infections occurring postoperatively in patients treated with tumor necrosis factor-alpha inhibitors for inflammatory arthritis: Report of three cases: J Hand Surg Am, 2010; 35(1); 104-8, pmid: 20117311
12.. Chopra N, Kirschenbaum AE, Widman D: J Clin Rheumatol, 2002; 8(5); 265-68, pmid: 17041383
13.. Abrams R, Savoia M, Vinetz J, Dacus AR, Indolent infectious tenosynovitis afflicting rheumatoid patients treated with tumor necrosis factor inhibitors: Case report: J Hand Surg Am, 2010; 35(6); 909-12, pmid: 20350799
14.. Lorenz HM, Dalpke AH, Deboben A: Arthritis Rheum, 2008; 59(6); 900-3, pmid: 18512727
15.. Hellinger WC, Smilack JD, Greider JL: Clin Infect Dis, 1995; 21(1); 65-69, pmid: 7578762
16.. Curtis JR, Patkar N, Xie A, Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists: Arthritis Rheum, 2007; 56(4); 1125-33, pmid: 17393394
17.. Sutker WL, Lankford LL, Tompsett R, Granulomatous synovitis: The role of atypical mycobacteria: Rev Infect Dis, 1979; 1(5); 729-35, pmid: 542760
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.949976
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950290
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950607
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950985
Most Viewed Current Articles
07 Dec 2021 : Case report
17,691,734
DOI :10.12659/AJCR.934347
Am J Case Rep 2021; 22:e934347
06 Dec 2021 : Case report
164,491
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
21 Jun 2024 : Case report
113,090
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
59,175
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133






